02. Success Pathway
Accelerated Vaccine Development: COVID-19 + Cancer
Partnering with the academic laboratory of Dr. Moutih Rafei of University of Montreal (Canada), Defence Therapeutics is focused on infectious disease and virus vaccine development utilizing the ACCUM™ platform for targeted drug delivery and effective treatments.
More potent than actual antigen (due to Accum™)
Possible Accum™ driven cost reduction of vaccine or ADC delivered – less drugs with better efficiency and efficacy.
Entirely scalable vaccine development approach – not limited to one indication:
Priority #1:
COVID-19 vaccine development
Priority #2:
Cancer vaccine, especially those with unmet medical needs.
Platform-driven targeting results in vaccine solutions applicable to any virus or infectious disease.
Possible Accum™ driven cost reduction of vaccine or ADC delivered – less drugs with better efficiency and efficacy.
Strong ability to produce follow-on products.
Overcomes major issue to date of non-targeted therapies.
Advanced Vaccines
Benefiting from the multiplier ability of Accum™ (100x), Defence Therapeutics can easily direct the science from one antigen to another resulting in rapid new formulations for any pandemic or disease: Covid 19, Cancer, Ebola, etc.
Accum™ technology enhances the delivery of protein/RNA/DNA inside the cytoplasm
It targets previously identified antigens and optimizes presentation and drug response
The platform allows for re-application of formulations to the latest viruses, for targeted efficiency and positive patient response.
Key milestones and next steps for Vaccine Development:
Target outcomes
- Phase 1 Health Canada trial candidacy